1. Nishida N. Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”. Clin Mol Hepatol 2024;30:682-688.
2. Cheon J, Kang B, Jung SH, Kim C, Chon H. Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment. J Clin Oncol 2023;41(4 Suppl):554.
5. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016;39:98-106.
6. Li Z, Li L, Zhong J, Cui K, Zhang C, Shi X, et al. Regorafenib combined with PD-1 monoclonal antibody in the second-line setting for hepatocellular carcinoma (HCC): A retrospective, real-world study in China. J Clin Oncol 2022;40(16 Suppl):e16145.
7. Ma L, Zhang Y, Fang Y, Hao C, Fan Q, Jiang D, et al. 959P Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial. Ann Oncol 2023;34(Suppl 2):S599-S600.
8. Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer 2022;167:1-12.
10. Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23:995-1008.
11. Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021;22:977-990.
16. Zhu M, Liu Z, Chen S, Luo Z, Tu J, Qiao L, et al. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study. Hepatology 2024;80:807-815.
17. Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice. Cancer Rep (Hoboken) 2023;6:e1679.
18. Muto H, Kuzuya T, Kawabe N, Ohno E, Funasaka K, Nagasaka M, et al. Clinical outcomes with lenvatinib in patients previously treated with atezolizumab/bevacizumab for advanced hepatocellular carcinoma. Anticancer Res 2023;43:4673-4682.